The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today


Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children

May 7, 2020 - 13:24 -- Open Access
Ding J, Coldiron ME, Assao B, Guindo O, Blessborn D, Winterberg M, Grais RF, Koscalova A, Langendorf C, Tarning J
Clin Pharmacol Ther. 2020 May;107(5):1179-1188

Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC. Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case‐control study to evaluate SMC effectiveness (n = 869).

In Vivo Activity of Amodiaquine against Ebola Virus Infection

January 15, 2020 - 07:58 -- Open Access
DeWald LE, Johnson JC, Gerhardt DM, Torzewski LM, Postnikova E, Honko AN, Janosko K, Huzella L, Dowling WE, Eakin AE, Osborn BL, Gahagen J, Tang L, Green CE, Mirsalis JC, Holbrook MR, Jahrling PB, Dyall J, Hensley LE
Scientific Reports, 2019 Dec 27; 9(1):20199

During the Ebola virus disease (EVD) epidemic in Western Africa (2013‒2016), antimalarial treatment was administered to EVD patients due to the high coexisting malaria burden in accordance with World Health Organization guidelines. In an Ebola treatment center in Liberia, EVD patients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compared to those treated with artemether-lumefantrine.

Not Open Access | Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African children

November 19, 2019 - 14:56 -- NOT Open Access
Junjie Ding, Matthew E. Coldiron, Joel Tarning, et al.
Clinical Pharmacology & Therapeutics, Volume 106, Issue 6

The developed methodology to evaluate adherence showed a sensitivity of 65‐71% when the first dose of SMC was directly observed and 71‐73% when no doses were observed in a routine programmatic setting. Adherence simulations and measured desethylamodiaquine concentrations in the case‐control children showed complete adherence (all doses taken) in less than 20% of children. 


Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013–2014 malaria season

March 4, 2015 - 15:06 -- Open Access
Bécaye Fall, Cheikhou Camara, Mansour Fall, Aminata Nakoulima, Pierre Dionne, Bakary Diatta, Yaya Diemé, Boubacar Wade, Bruno Pradines
Malaria Journal 2015, 14:60 (6 February 2015)

The prevalence of isolates with a reduced susceptibility to MQ remains high and stable in Dakar. Since 2004, the prevalence of CQ resistance decreased, but rebounded in 2013 in Dakar. PND, PPQ and PVB showed high in vitro activity in P. falciparum parasites from Dakar

A pilot study on quality of artesunate and amodiaquine tablets used in the fishing community of Tema, Ghana

July 3, 2013 - 12:51 -- Open Access
Affum AO, Lowor S, Osae SD, Dickson A, Gyan BA, Tulasi D
Malaria Journal 2013, 12:220 (28 June 2013)

A pilot study on the quality of anti-malarial tablets in circulation during the major fishing season at a malarious fishing village located along the coast of Tema in southern Ghana was determined.


Artesunate/Amodiaquine Malaria Treatment for Equatorial Guinea (Central Africa)

June 6, 2013 - 15:41 -- Open Access
Pilar Charle, Pedro Berzosa, Aida de Lucio, José Raso, Gloria Nseng Nchama and Agustín Benito
Am J Trop Med Hyg 2013 88:1087-1092

Our study showed the good efficacy of combination AS/AQ therapy. This finding enabled this treatment to be recommended to Equatorial Guinea's National Malaria Control Program to change the official treatment policy as of March 2008.

NOT Open Access | Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold

January 22, 2013 - 07:52 -- NOT Open Access
Claire-Lise Ciana, Romain Siegrist, Christoph Boss, et al.
Bioorganic & Medicinal Chemistry Letters, Volume 23, Issue 3, 1 February 2013, Pages 658–662

A novel series of anti-malarials, based on a hydroxy-ethyl-amine scaffold, initially identified as peptidomimetic protease inhibitors is described.

A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs

November 12, 2012 - 08:55 -- Open Access
Orjuela-Sánchez P, Duggan E, Nolan J, Frangos JA, Carvalho LJ
Malaria Journal 2012, 11:366 (5 November 2012)

This ELISA-based in vitro drug assay is easy to implement, fast, and avoids the use radioisotopes or expensive equipment.

Medical Treatment: 
Subscribe to RSS - amodiaquine